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Background: Mithramycin is a member of the clinically important aureolic 
acid group of antitumor drugs that interact with GC-rich regions of DNA 
nonintercalatively. These drugs contain a chromophore aglycon that is derived 
from condensation of ten acetate units (catalyzed by a type II polyketide 
synthase). The aglycones are glycosylated at two positions with different chain 
length deoxyoligosaccharides, which are essential for the antitumor activity. 
During the early stages of mithramycin biosynthesis, tetracyclic Intermediates of 
the tetracycline-type occur, which must be converted at later stages into 
the tricyclic glycosylated molecule, presumably through oxidative breakage 
of the fourth ring. 
Results: Two intermediates in the mithramycin biosynthetic pathway, 4-demethyl- 
premithramycinone and premithramycin 6, were identified in a mutant lacking the 
mithramycin glycosyltransferase and methyltransferase genes and in the same 
mutant complemented with the deleted genes, respectively. Premithramycin B 
contains five deoxysugars moieties (like mithramycin), but contains a tetracyclic 
aglycon moiety instead of a tricyclic aglycon. We hypothesized that transcription 
of mtmO/l/ (encoding an oxygenase) was impaired in this strain, preventing 
oxidative breakage of the fourth ring of premithramycin 9. Inactivating mfmO/V 
generated a mithramycin nonproducing mutant that accumulated premithramycin 
B instead of mithramycin. In vitro assays demonstrated that MtmOlV converted 
premithramycin B into a tricyclic compound. 
Conclusions: In the late stages of mithramycin biosynthesis by 
Strepyomyces argillaceus, a fully glycosylated tetracyclic tetracycline-like 
intermediate (premithramycin B) is converted into a tricyclic compound by the 
oxygenase MtmOlV. This oxygenase inserts an oxygen (Baeyer-Villiger 
oxidation) and opens the resulting lactone. The following decarboxylation and 
ketoreduction steps lead to mithramycin. Opening of the fourth ring represents 
one of the last steps in mithramycin biosynthesis. 
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Introduction 
The aureolic acid group of antitumor agents is comprised 
of mithramycin, chromomycin, olivomycins, chromo- 
cyclomycin and ITCH9 [l-6]. They interact with @Z-rich 
regions of DNA in a non-intercalative way in the presence 
of Mgz+. which is essential for activity [7,8]. 1,lilithramycin 
is the only aureolic acid drug used clinically. It shows a 
remarkable cytotoxicity against a variety of tumor cell 
lines and has been used in the treatment of certain 
tumors, including disseminated embryonal cell carcinoma 
and Paget’s bone disease. Ir is also used to control hyper- 
calcemia in patients with malignant diseases [4,5]. 
Structurally, all the members of the group (with the 
exception of chromocyclomycin) consist of a tricyclic 
chromophore that is glycosylated at two different posit- 
ions of the aglycon with saccharides of various chain 
lengths (Figure 1). Chromocyclomycin differs in having a 
tetracyclic instead of a tricyclic chromophore. The 
polyketidt: aglycon of these compounds is derived from 
the condensation of ten acetates in a series of conden- 
sation reactions catalysed by a type II polyketide synthase 
[9-111. Early reports suggested that the aureolic acid 
aglycon could be derived from the condensation of two or 
even three independently synthesized polyketide chains 
[12,1.3]. This hypothesis WAS ruled out, howe\-er, on the 
basis of rt.sults of two heterologous expression experi- 
ments. Ex~ession of the mithramycin ketoacylsynthase 
(mtmP) and chain length factor tvzmh7 genes in Sfrppto- 
nqwes coeli~o/or CH999. an appropriately engineered 
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Figure 1 
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Structures of the aureolic acid group of 
antitumor agents. 
expression host, led to the formation of the ZO-carbon ring [9,15-171. It was not clear when this oxidative cleav- 
polyketides RM20b,c [9], and expression of the mithra- age should take place, however-before, during or after 
mycin minimal polyketide synthase alone in &‘. lividam glycosylation. Recently, several glycosylated inter- 
produced SEKlS [14]. Isolation of premithramycinone mediates of the mithramycin pathway have been isolated 
and its nonmethylated derivative 4-demethyl-premith- through the insertional in,activation of two genes (mtmGi 
ramycinone from a mutant blocked at early steps in and rn~&Zfl that code for the two glycosyltransferases 
6-deoxysugar biosynthesis showed that biosynthesis of responsible for disaccharide formation and its transfer to 
mithramycin proceeds through tetracyclic tetracycline- the aglycon [18]. Three of these intermediates were tetra- 
like intermediates [15]. It was proposed that transfor- cyclic compounds containing one sugar (premithramycin 
mation of the tetracyclic into the tricyclic chromophore At), two sugars (premithramycin A2) or three sugars 
could occur through an oxidative cleavage of the fourth (premithramycin A.31 attached to the C-12a-0 of the 
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aglycon. The last compound (premithramycin A4) resem- 
bled premithramycin A3, except that the fourth ring was 
already open. Here we report the cloning, sequencing, 
expression and insertional inactivation of a gene, mtmOl~‘, 
from the mithramycin producer S. argi//aceus that codes 
for an oxygenase. Several lines of experimental evidence 
show that action of this oxygenase leads to the breakage 
of the fourth ring of an inactive biosynthetic intermediate, 
premithramycin B, and that this event occurs after com- 
plete formation of both oligosaccharide chains. 
Results and discussion 
The mtmOlV gene encodes an oxygenase 
The mithramycin biosynthetic gene cluster has been iso- 
lated within three overlapping cosmid clones of genomic 
DNA from the mithramycin producer S. argihceus. It 
extends over -50 kilobases (kb) and contains 34 genes 
[ll]. At the right-hand side of the cluster two genes 
(mtmCII and mtmGI) that encode glycosyltransferases 
responsible for the transfer of the I,-olivose disaccharide 
to the aglycon [18] and four genes (mtrX, tntrY, mtrA and 
mtrB) involved in resistance to and secretion of 
mithramycin [19] have been cloned and characterized. 
We have now sequenced a 2.1 kb Ram131 fragment 
located (and partially overlapping) between the mtmC/ 
and mtrX genes (Figure Za). Analysis of the sequence 
Figure 2 
using the CODONPREFERENCE program [ZO] reveal- 
ed an open reading frame (named mtmOlL’) with the char- 
acteristic codon usage of Streptomyces genes. The mtmOZV 
gene is comprised of 1602 nucleotides and would code for 
a 534 amino acid polypeptide with an estimated molecu- 
lar weight (h4,) of 57,128. There are two potential consec- 
utive ATG starting codons for mtmOZl’ thar overlap the 
stop codon of nrtmG/. Between mfmOlV and mtrX there is 
an inter,:enic region of 70 nucleotides that. when analy- 
sed using the STEMLOOP program [ZO], has a long 
inverted repeat sequence capable of forming a stem-loop 
seconda-y structure that has a formation energy of 
-19.2 kcal/mol (calculated using the FOLD progmm 
1211). This stem-loop probably functions as a transcrip- 
tional terminator, as has been described previously in 
Streptomyes species [22,23]. Therefore, mtmO/V, together 
with tnt~C/, might form part of the same transcriptional 
unit transcribed independently of mtrX. Comparison of 
the deduced product of mtmO/V with databases using the 
BLAST program [24] revealed similarities with various 
oxygenases: 44% identity with the JadORFh oxygenase of 
the jadomycin pathway from S. venezuelae [ZS], 44% 
identity with the Iri protein of RAodoco~us equi involved 
in resistance to rifampicin 1261. 43% identity with the 
IJrdE oxygenase of the urdamycin pathway from S. ftu- 
dine [27] and 33.1% identity with the RdmE oxygenase 
(a) Schematic organization of the region of 
the mithramycin biosynthetic gene cluster that 
surrounds the mtmO/V gene. 6, BarnHI; F, 
Fspl; G, BgAl; N, Nod; P, fsd; S, SaA; X, Xhol. 
The restriction sites indicated with an asterisk 
are not unique sites in the region shown. 
Designations for the genes are as follows: V 
and W represent the mtmVand mtmWgenes, 
which are sugar biosynthetic genes; MI and 
MII represent the mfml and mfmll genes that 
encode methyltransferases; GI, GII, Glll and 
GIV represent the mfmG/, mfmG//, mfmG/ll 
and mfmG/Vgenes that encode 
glycosyltransferases; X, Y, A and B represent 
the mfrX, mfrV, mfrA and mfrB genes involved 
in mithramycin resistance and secretion. 
(b) Pile-up comparison of the amino-acid 
sequences of different oxygenases showing 
the two motifs present in many FAD- and 
NADPH-dependent enzymes. JadORF6, 
jadomycin hydroxylase from S. venezuelae 
[25]; UrdE, urdamycin hydroxylase from 
S. fradiae [27]; Iri, oxygenase from 
/?hodococcus equi involved in resistance to 
rifampicin [26]; RdmE, rhodomycin 
hydroxylase from S. purpurascens [28]; 
MtmOlV, mithramycin oxygenase (this paper). 
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from the rhodomycin pathway in S. purpurascens [28]. All 
of these oxygenases contain two conserved motifs that 
are characteristic of flavin-type hydroxylases (Figure 2): a 
region very close to the amino terminus (Figure Zb), the 
so-called Pa@ fold, that is involved in binding of the 
ADP moiety of FAD [29] and a second region that is 
believed to be involved in the binding of the ribityl 
chain of FAD [30,31]. 
According to isotope-labeling studies using l-I%, 1802- 
labeled acetate and fermentation under 1802, three of the 
oxygens in the aureolic acid aglycon are derived from 
molecular oxygen and the rest of them are derived from 
acetate oxygen atoms [ll]. Consequently, we initially 
thought that the MtmOIV oxygenase might introduce 
some of these oxygens into the aglycon. Three other 
oxygenases have been identified in the mithramycin bio- 
synthetic cluster, however. ‘Two of the oxygenases 
(MtmOI and ~CltmOIII) do not seem to be essential in 
the pathway as their inactivation does not affect 
mithramycin biosynthesis 1171. The third oxygenase, 
MtmOII, is probably responsible for introducing two 
hydroxyl groups into 4-demethyl-premithramycinone 
[ 171. On this basis, and to assign a role for the MtmOIV 
oxygenase in mithramycin biosynthesis, MtmOIV was 
tentatively proposed as a candidate for catalysing the 
oxidative cleavage of the fourth ring of the aglycon of the 
mithramycin precursor. 
Figure 3 
A mutant lacking the mithramycin glycosyltransferases and 
methyltransferases is impaired in mfmO/W expression 
A clue to the possible involvement of MtmOIV oxygenase 
in fourth-ring breakage arose serendipitously during the 
course of insertional inactivation experiments in the 
mithramycin glycosyltransferase region. To determine the 
individual role of the four glycosyltransferase genes 
(mtmGI, mtmG//, mtmGlII and mtmGIlr) in sugar transfer 
during mithramycin biosynthesis, a deletion mutant 
lacking the four glycosyltransferase genes (and the two 
methyltransferase genes located between mtmGIII and 
mtmGZZ; Figure 2a) was generated using the plasmid 
construct pEFAMG. The construct consisted of an 
erythromycin resistance cassette flanked by S. qihz~eus 
genomil:: DNA from just outside the glycosyltransferase 
and methyltransferase region (Figure 3). After transform- 
ing S. q3’/aceus protoplasts with this construct, several 
erythromycin-resistant thiostrepton-sensitive colonies 
were obtained (thiostrepton was the antibiotic marker in 
the plasmid and erythromycin was the marker used to 
select for the replacement). Southern blot hybridization 
verified that these recombinant strains had arisen as a con- 
sequence of a Campbell-type double crossover that 
deleted the wild-type gcnomic DNA region. High- 
performance liquid chromatography (HPLC) analyses of 
culture supernatants of these recombinant strains revealed 
that they did not produce mithramycin but instead 
accumulated 4-demethyl-premithramycinone (Figure 3). 
S. ai-@iaceus chromosome 
x x 
ti.w olv.3 
. OH 
I, ““xp-$q, 
HO OH0 0 0 
4-demethybpremithramycinone 
+ 
+ pG14MlZ 
Evidence for a role of MtmOlV in fourth ring 
breakage. The M3AMG mutant was generated 
by deleting four glycosyltransferase and two 
methyltransferase genes from the chromosome 
of S. argillaceus; this mutant accumulated 
4-demethyl-premithramycinone instead of 
mithramycin. Complementation experiments 
with a plasmid expressing all these genes 
produced premithramycin B. Fourth-ring 
breakage and conversion of premithramycin B 
into rnithramycin was enabled by further 
cloning and expression of mfmO/V gene. 
p, erythromycin resistance promoter. 
+ 
OH 
+ pEF0-i 
r 
Strain EF14124 
,‘- P Xl L 
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This is a tetracyclic compound that lacks sugars and the 
two methyl groups at the C-4-O and C-9 of the aglycon 
[15]; the methyl groups are present at these positions in 
premithramycins AZ, A3 and B, as well as in the corre- 
sponding positions of the mithramycin aglycon. These two 
methyl groups are introduced by two methyltransferases 
coded by the mtmMi (0-4-methylation) and mtmMII 
(C-9-methylation) genes (M.J. Fernandez Lozano, CM. 
and J.A.S., unpublished observations). 
In order to verify that in the generation of this mutant 
(named M3AMG) only the deleted glycosyltransferase and 
methyltransferase genes were affected, we carried out a 
complementation experiment. An 8 kb B$II-XhoI DNA 
fragment (sites 3-11 in Figure Za) containing the four gly- 
cosyltransferase and two methyltransferase genes was sub- 
cloned into the expression vector pEM4. In this construct, 
expression of the mtmGIV, mtmGI/I, mtmM(I and mtmM1 
genes was controlled by the erythromycin resistance pro- 
moter (ermE”) and the mtmGiI and mtmG/ genes were 
controlled by their own divergent promoters. This plasmid 
construct (pG14M12; Figure 3) was used to transform pro- 
toplasts of the M3AMG mutant strain and several transfor- 
mants were analysed for the production of mithramycin 
using HPLC. Most of them produced mithramycin but 
normal levels of drug production were not restored, 
indicating that transcription of other gene(s) was probably 
impaired in these clones. Some of the transformants 
showed a new HPLC peak with a higher retention time 
than most of the mithramycin intermediates isolated thus 
far. In one of the transformants (strain EF1412) the new 
peak was also the major peak. After purification of the 
material present in this peak its structure was elucidated 
using nuclear magnetic resonance (NMR) and mass 
spectroscopy (MS; see below) and found to be a tetracyclic 
compound containing both methyl groups at C-4-O and 
C-9 and both oligosaccharide chains attached at the appro- 
priate positions in the aglycon (Figure 3). This compound, 
designated premithramycin B, differs from mithramycin 
only in the aglycon moiety, which is tetracyclic in contrast 
to the tricyclic aglycon of mithramycin, and in the 4’-OH 
group present in mithramycin. The corresponding l’-car- 
bony1 group in premithramycin B is unreduced. This fact, 
together with the genomic location of mtmO/V, 
immediately downstream of mtmGZ, prompted us to con- 
sider that perhaps expression of the gene encoding the 
enzyme responsible for breaking the fourth ring was 
impaired inathe recombinant strain EF1412, which in turn 
suggested that the MtmOIV oxygenase might oxidatively 
cleave the fourth ring. To test this hypothesis we sub- 
cloned the mtmOZV gene alone under the control of the 
emnE* promoter (pEFOIV) and transformed protoplasts of 
strain EF1412 (strain M3AMG, which contained 
pG14M12 with the glycosyltransferase and methyltrans- 
ferase genes). All the transformants recovered the normal 
levels of mithramycin production (see strain EF14124 in 
Figure 3), suggesting that the MtmOIV oxygenase was 
impaired in the EF1412 strain, probably because its 
normal tl-anscription was affected. The conclusion from all 
these experiments is that the mtmOIV gene codes an oxy- 
genase that presumably is responsible for the breakage of 
the fourth ring of premithramycin B as one of the last 
steps in the mithramycin biosynthesis. 
Insertional inactivation of mfmO/Vgene precludes fourth 
ring breakage 
To obtain further and del<nitive evidence for the involve- 
ment of MtmOIV in fourth ring breakage, the M3AO4 
mutant was generated by deleting an internal fragment of 
mtmOZV and replacing it with an apramycin resistance cas- 
sette (see, the Materials and methods section). After trans- 
forming S. a&‘actu protoplasts with the appropriate 
construct (pLPAO4) 11 apramycin-resistant transformants 
were obtained, two of which were simultaneously 
thiostrepton-sensitive, suggesting that they were the con- 
sequence of a double crossover. This was verified by 
Southern blot hybridization. HPLC analysis of culture 
supernatant of one of these mutants (M3A04) showed that 
premithramycin B accumulated instead of mithramycin. 
To clear]>. determine that the gene replacement event only 
affected the mtmO/V gene and not other genes, mtmOW 
was subcloned into the shuttle vector pIAGO under the 
control of the erythromycin resistance promoter (pLPO4) 
and introduced by transformation into M3AO4. In all the 
tmnsformants obtained production of mithramycin was 
restored, indicating that the accumulation of premithra- 
mycin B by this mutant was the consequence of inactiva- 
tion of the mtmOIV gene. 
The MtmOlV oxygenase causes in vitro oxidative breakage 
of the fourth ring of premithramycin B 
Biochemical confirmation of the fourth-ring cleavage of 
premithrdmycin B by the MtmOIV oxygenase was 
obtained after expressing the mtmOIV gene and using it in 
in aitro enzymatic assays. pLPO4 was transformed into 
S. alh p:otoplasts and cell-free extracts of one of the 
transformants (strain LPO4) were fractionated by ammo- 
nium sulphate precipitation. Breakage of the fourth ring of 
premithranycin B was then assayed as described in the 
Materials and methods section. Premithramycin B 
(Figure 4a:l was converted into a new compound with an 
HPLC retention time very close to that of mithramycin 
(Figure 4b). The absorption spectrum of this new com- 
pound (ii in Figure 4~:) was identical to that of 
mithramycin but differed from premithramycin B (i in 
Figure 4~) in being displaced to shorter wavelengths, sug- 
gesting that, in the new compound, fourth-ring breakage 
had occurred. When premithramycin B was incubated 
with extracts from the control strain (strain IAGO, which 
contained only the vector), no modification of premith- 
ramycin B was observed (data not shown). Most of the 
activity wd:i detected in the 25110% protein fraction of 
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Figure 4 
HPLC analysis of the reaction catalysed by 
the MtmOlV oxygenase. (a) Chromatogram of 
premithramycin 6. (b) Chromatogram of the 
reaction mixture after 2 h of incubation. 
(c) Absorption spectra of peaks (i) and (ii). 
Time (min) Time (mm) Wavelength (nm) 
Chewtry 8 Biology 
strain LP04. The addition of either NADH or NADPH 
was absolutely necessary for activity, with the requirement 
for NADPH much higher than that for NADH (data not 
shown). Breakage of the fourth ring of premithramycin B 
did not render the final molecule mithramycin. In addition 
to the oxidative ring cleavage, loss of one carbon unit, pre- 
sumably as CO,, must occur, and this might take place 
spontaneously. Furthermore, a reductive step is required 
to form the 4’-OH group of mithramycin (Figure 5). Con- 
sequently, the action of the MtmOIV oxygenase would 
render an intermediate compound between premithrd- 
mycin B and Imithramycin, probably the substrate for a 
ketoreductase that would catalyse the final step in the 
mithramycin biosynthesis. Candidates for this ketoreduc- 
tion step could be the products of mtmTI [lo], mtm7’/1 or 
Figure 5 
-____ 
r -1 
O~,p,p./ACP 1 
rntmTII~’ 1171 ketoreductase genes, for which clear and 
definitive functions halve not yet been assigned in 
mithramycin biosynthesis. 
Structure elucidation of premithramycin B 
The structure of premitbramycin B was elucidated using 
physicochemical methods. The negative fast atom bom- 
bardment (FAB) MS (m/z 1092, M-H-) in combination with 
the ‘H- and the I%-NMR spectra indicated the molecular 
formula CSiH7ZOZ,. The ‘H- and ‘%2-N\IR spectra also 
revealed the presence of five sugar moieties (recognizable 
in particular from the anomeric carbon signals at 6 101.4, 
100.7,98.4, 9X.3, 96.9) and the 9-methyl group (6,, 2.15 s; 6,: 
8.4 q). The ultraviolet spectrum, as well as further NhlR 
data of the aglycon moiety, was almost identical to those of 
Proposed mechanisms for the MtmOlV 
oxygenase reaction and the following steps. 
RO 
This Elaeyer-Villiger monoc 
mechanism is consistent with the in vitro 
studies of MtmOlV, which require NADPH as 
a cofactor. 
Premithramycin 6: R’ = Trisaccharide Chain, 
R2 = Diicchatide Chain 
02a NADPH - 
H20, NADP+ + 
MITHRAh4YCIN 
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Table 1 - 
1H NMR data of premithramycin B comparison to premithramycin A3 and mithramycin in dg-acetone, 6 in ppm relative to TMS (1 in Hz). 
Premithramycin B’ Premithramycin A3’ Mithramycin’ 
2-H 
3-H 
4-H 4.21 br 4.04 s br+ 
4-OMe 
4a-H 
5-H 
3.53 s# 
3.16 m 
a: 3.98 br d (17) 
e: 3.13 br d (17) 
6.96 s 
6.63 s 
2.13 s 
3.52 s 
4.75 d (11.5) 
2.76 dddd 
(11.5, 11, 3, 1.5) 
a:2.84-2.885 
e:2.63 dd (16, 3) 
6-H 
7-H 
7-Me 
9-H 
9-CH, 
1 O-H 
l’-H 
1 ‘-OMe 
2’.H, 
3’-H 
4’-H 
5,-H, 
IA-H 
2A-H* 
2A-H, 
3A-H 
4A-H 
5A-H 
6A-H, 
1 B-H 
2B-H* 
2B-H, 
3B-H 
4B-H 
56-H 
6B-H, 
lC-H 
2C-H’ 
2C-H, 
3C-H 
4C-H 
5C-H 
6C-H, 
1 D-H 
2D-H’ 
2D-H, 
3D-H 
4D-H 
5D-H 
6D-H, 
lE-H 
2E-H* 
2E-H, 
3E-Me 
4E-H 
5E-H 
6E-H, 
3.12 ddd (11, 4, 3) 
a: 3.79 ddd (16.5, 4, 1) 
e: 3.05 dd (16.5 , 3) 
6.93 d (1) 
6.71 s 
6.82 s 
2.11 s 
- 
2.16 s - 
6.80 s 
4.85 d (1.5) 
3.44 s 
2.65 br s 2.59 s 
5.42 dd (10, 2) 
1.88 ddd (12, 12, 10) 
2.50 ddd (12, 5, 2) 
3.87 ddd (12, 8.5, 5) 
3.09 dd (9, 8.5) 
3.77 dq (9, 6) 
1.35 d (6) 
4.77 dd (10, 2) 
1.58 ddd (12.5, 12, 10) 
2.21 ddd (12.5, 5, 2) 
3.60 ddd (12, 9, 5) 
3.01 dd (9, 9) 
3.42 dq (9, 6)c 
1.35 d (6) 
5.00 br d (10) 
1.80 ddd (12, 12, 10) 
2.79 m br 
3.67 md 
3.03 dd (9, 9) 
3.43 dq (9, 6)* 
1.39 d (6) 
4.69 dd (10, 2)’ 
1.75 ddd (12.5, 12, 10) 
1.92 ddd (12, 4.5, 2) 
3.90 ddd (12.5, 4.5, 3) 
3.71 s br 
3.70 q (6.5)s 
1.28 d (6.5) 
4.95 dd (9.5, 2) 
1.52 dd (13.5, 9.5) 
1.87 dd (13.5, 2) 
1.20 s 
2.93 d (9.5) 
3.63 dq (9.5, 6.5) 
4.88 dd (9.5, 2) 
1.55 ddd (12, 12, 9.5) 
2.55 m br 
3.55 ddd (12, 8.5, 5:)s 
2.90 dd (9, 8.5)# 
3.29 dq (9, 6) 
1.24 d (6) 
4.62 dd (10, 2) 
1.74 ddd (12, 12, 10) 
1.90 ddd (12, 4.5, 2: 
3.86 ddd (12, 4.5, 3: 
3.69 s 
3.67 q (6.5) 
1.26 d (6.5) 
4.94 dd (9.5, 2) 
1.52 dd (13.5, 9.5) 
1.86 dd (13.5, 2) 
1.20 s 
2.91 d (9.5)# 
3.62 dq (9.5, 6) 
4.23 d (2.5) 
4.21 dq (6.5, 2.5) 
1.26 d (6.5) 
5.21 dd (10, 2) 
1.79 ddd (12, 12, 10) 
2.29 ddd (12, 5, 2) 
3.60-3.757 
3.04 dd (9, 9) 
3.49 dq (9, 6) 
1.32 d (6) 
4.68 dd (10, 2) 
1.54 ddd (12, 12, 10) 
2.18 ddd (12, 5, 2) 
3.58 ddd (12, 9, 5) 
2.94 dd (9, 9) 
3.40 dq (9, 6)* 
1.29 d (6) 
5.10 dd (10, 2) 
1.61 ddd (12, 12, 10) 
2.56 ddd (12, 5, 2) 
3.60 rn§ 
2.94 dd (9, 9) 
3.31 dq (9, 6)* 
1.29 d (6) 
4.67 dd (10, 2) 
1.78 ddd (12, 12, 10) 
1.94 ddd (12,4.5, 2) 
3.88 ddd (12, 4.5, 3) 
3.72 s br 
3.70 q (6.5)s 
1.29 d (6.5) 
4.96 dd (9.5, 2) 
1.54 dd (13.5, 9.5) 
1.89 dd (13.5, 2) 
1.22 s 
2.94 d (9.5)#1 
3.64 dq (9.6, 6) 
1.21 d (6.5) 1.20 d (6) 1.22 d (6) 
OH signals for premithramycin B: 6 3.26, 4.70 and (all 4.70, 9.41 broad s). OH signals 4.11, 4.20, ~4.64, 9.80 and 15.9 (all broad s); br *at 500 = fo  premithraycin A3: 6 14.9 broad +at 300 broad; MHz; 
4.59, 9.50, 9.90, (all s); OH signals MHz; *assignments for mithramycin: 6 3.23, 3.75, interchangeable; komplex, partially 
3.82, 3.91, 3.92, 4.10, obscured; #broad, partially obscured; komplex, overlapping signals. 
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Table 2 
1% NMR data of premithramycin B compared to 
premithramycin A3 and mithramycin, in de-acetone at 125.7 
MHz, 6 in ppm relative to internal TYS, multiplicities and 
assignments from the APT, HMQC and HMBC experiments. - 
Prelnithramvcin B Premithramvcin A3 Mithramycin* - 
203.1 s 
75.9 d 
41.7 d 
26.4 t 
135.5 s 
C-l 
c-2 
c-3 
c-4 
C-4a 
4-OCH, 
c-5 
G5a 
C-6 
C-6@ 
c-7 
7-CH, 
C-8 
C-8a 
c-9 
C-9a 
9-CH, 
c-10 
C-1Oa 
c-11 
C-l la 
c-12 
C-12a 
C-l’ 
1 ‘-OCH, 
C-2’ 
C-3’ 
c-4 
C-5’ 
C-1A 
C-2A 
C-3A 
C-4A 
C-5A 
C-6A 
G1B 
C-2B 
G3B 
C-4B 
C-5B 
c-6B 
c-1c 
c-2c 
c-3c 
c-4c 
c-5c 
C-6C 
C-1D 
C-2D 
C-3D 
C-4D 
C-50 
C-6D 
C-1E 
C-2E 
G3E 
SE-CH, 
C-4E 
C-5E 
C-6E 
196.7 s+ 
113.2s 
189.1 S+ 
78.5 d 
42.8 d 
61.9 q 
26.4 t 
134.6 s 
118.8 d 
139.8 s 
101.4 d 
196.2 s+ 
113.2s 
189.0 s+ 
78.0 d 
43.0 d 
61.4 q 
26.6 t 
134.6 s 
117.8 d 
140.1 s 
102.8 d 
100.7 d 
158.8 s 
160.6 s 162.1 s 
111.4s 110.7 s 
110.0s 
7.0 q 
155.2 s 
107.0 s 
164.2 s 
107.6 s 
8.4 q 
156.6 s 
107.9 s 
166.6 s 
109.0 s 
193.5 s+ 
86.1 s 
204.3 s 
6.2 q 
157.5 s 
107.1 s 
168.0 s 
108.0 s 
193.0 s+ 
85.5 s 
204.3 s 
116.2d 
138.0 s 
28.6 q 28.4 q 
96.9 d 
:3a.1 t 
82.2 d 
76.0 d 
72.9 d 
18.7 q4 
100.7 d 
40.4 t 
71.8 d 
78.0 d 
73.2 d 
18.2 q 
98.5 ds 
39.3 t 
82.1 d 
76.0 d 
7:3.0 d 
16.8 q* 
100.7 d 
32.7 t 
77.1 d 
69.3 d 
71.5 d 
17.0 q 
98.3 d§ 
44..7 t 
71.1 s 
27.5 q 
77 2 d 
71.4d 
18.‘7 q” 
98.3 d# 
38.5 t 
81.9 d 
75.6 d 
72.8 d 
18.5 q 
100.5 d 
32.8 t 
77.1 d 
69.2 d 
71.2 d 
16.9 q 
98.2 dX 
44.6 t 
71.1 s 
27.7 q 
77.1 d 
71.3 d 
16.7 q 
81.1 d 
57.8 q 
210.6 s 
78.4 d 
67.5 d 
18.7 q 
95.7 d 
36.5 t 
80.6 d 
74.5 d 
71.5 d 
17.2 q 
99.1 d 
39.1 t 
70.4 d 
76.6 d 
71.7 d 
16.8 q 
100.0 d 
37.0 t 
80.8 d 
74.8 d 
71.6d 
17.1 q 
99.3 d 
31.6 t 
75.8 d 
68.0 d 
70.0 d 
15.6 q 
97.1 d 
43.4 t 
69.8 s 
26.1 q 
76.1 d 
70.1 d 
17.4 q 
Table 2 footnote 
*Assignments could not be further confirmed, because the sample 
precipitated after the broad-band decoupled W-NMR spectrum was 
determined; thus many assignments of similar chemical shift may be 
interchangeable; +.*,§,#assignments interchangeable. 
the premithramycins A2 and A3 [18], indicating the same 
tetracyclic aglycon. Typical for this aglycon is the ace@ 
group (C-l’, C-Z’), the OCH, group at C-4, two aromatic 
protons of the C and D rings, one aromatic bound methyl 
group (6, 2.15; 6,: 8.4). and six sp?-carbons attached to an 
oxygen atom. in addition to the carbonyl of the acetyl 
sidechain. As a result of this arrangement, an intensive 
tautomerism can be observed. As a consequence some of 
the carbons (C-l, C-3, C-11, C-12) typically show broad 
signals or variation of their chemical shifts and cannot be 
assigned unambiguously due to the lack of observable 
long-range C-H couplings. The NMR data of these sac- 
charide moieties are identical to the corresponding ones of 
mithramycin; for example, the IH NMR signals of the 
anomeric protons indicate P-glycosidic linkages (all five 
1-H signals show a 10 Hz transaxial coupling to the neigh- 
boring Z-H,). Typical signals indicate the mycarose (e.g. 
the 3E-Me signal at 6 1.20; 4E-H at 6 2.93), the oliose (e.g. 
the bro.dd singlet of 4D-H at 6 3.71) and the three olivose 
moieties (e.g. Z-H, signals at 6 2.21, 2.5 and 2.79 or the 
4-H ‘triplets’ at 6 3.01, 3.03 and 3.09). The interglycosidic 
links are clear from the heteronuclear multiple bond con- 
nectivity (HMBC) speclzrum, which proves that they are 
arranged as one trisaccharide (p-n-olivose-3-1-fi-n-oliose-3- 
I-&[I-mycarose) and one disaccharide (P-t>-olivose-3-l- 
p-D-olivose) chain. The linkage positions of these 
saccharide moieties to the aglycon are also indicated from 
the HMBC spectrum. The most important .i.lc,-ll-couplings 
are: lA-H-XX, 3A-H-C-lB, lB-H-tC-3A, lC-H+ 
C-12a, .X-H-X-lD, lD-H+C-3C, 3E-H-S-3D. The 
complete NMR signals of premithramycin B in comparison 
with prernithramycin A3, as well as mithrarnycin are shown 
in Tables 1 and 2. 
The MtmOlV oxygenase catalyses one of the last steps in 
mithramycin biosynthesis 
Most of the intermediates in mithramycin biosynthesis 
are tetracyclic compounds (some of which are glycosy- 
lated); premithramycin B is the last tetracyclic compound 
in the pathway (Figure 6). Conversion of premithramycin 
B into mithramycin occurs in the last steps of mithra- 
mycin biosynthesis. The MtmOIV oxygenase that caraly- 
ses this reaction can also accept at least one other 
substrate. Premithramycin A4 (Figure 6) is a tricyclic 
compounsd in which the fourth ring breakage has already 
occurred. It contains the trisaccharide at C-2-O but lacks 
the disaccharide at C-6-0. This compound was isolated 
as a minor compound from two mutants in which the 
rnt~GI and rn~mG1I genes were independently inacti- 
vated [18]. Premithramycin B must be the preferred 
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Figure 6 
Proposed biosynthetic pathway for the 
biosynthesis of mithramycin. 
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substrate for this oxygenase as it accumulates drama- 
tically when the mtmOIV gene is inactivated. 
Premithramycin B does not have detectable antibiotic 
activity (50 yg did not cause inhibitory effect on X&o- 
coccus Lzcteus in a bioassay) in contrast to the very potent 
inhibitory effect of mithramycin (0.1 pg caused a big in- 
hibition zone of M. l~teus growth). Survival of S. argillaceus 
during mithramycin biosynthesis depends on an ABC 
transporter system, coded by the mtrA and mtrB genes, 
that participates in the export of the drug through the cell 
membrane (inactivation of mtril produces a mithramycin- 
sensitive mutant) (191. This transport system is very spe- 
cific for mithramycin as it does not confer resistance co the 
structurally closely related aureolic acid drugs olivomycin 
and chromomycin [19]. The oxidative cleavage of 
premithrarnycin B by the MtmOIV oxygenase followed by 
decarboxylation and ketoreduction steps releases the toxic 
lethal drug mithramycin into the cytoplasm of 
5’. a@/ams. To ensure its Isurvival, the producer organism 
probably has to channel the active drug into the ABC 
transporter secretion system. This would probably require 
the MtmOIV oxygenase to be proximal to the cell mem- 
brane. It is worth mentioning that immediately upstream 
of the mtril gene is another gene, mtrY, to which function 
has not yet been assigned. Its deduced product showed 
similarity with a family of proteins designated as ankyrins 
(30.6% identity in a 36 amino-acid overlapping region with 
a human erythrocyte ankyrin) [.L?]. The ankyrins are a 
family of proteins found widely in eukaryotes that include 
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structural proteins that participate in linking the spectrin 
skeleton of human erythrocytes to the cytoplasmic surface 
of the cell membrane [33]. It is possible that the MtrY 
protein participates in establishing a physical linkage 
between the MtmOIV oxygenase (and a ketoreductase) 
and the ABC secretion system, which might facilitate the 
channeling of some intermediates in the final steps of 
mithramycin biosynthesis. 
Significance 
The biosynthesis of the aureolic acid group of antitumor 
drugs proceeds at early stages through tetracyclic interme- 
diates of the tetracycline-type that must be converted at 
later stages into the final tricyclic glycosylated molecule. 
We have shown here that one of the last intermediates in 
mithramycin biosynthesis, premithramycin B, a fully gly- 
cosylated tetracyclic compound, accumulates in the 
culture supernatant of mutants in which expression of 
the MtmOIV oxygenase gene has been affected. Because 
MtmOIV oxidatively cleaves the fourth ring in 
premithramycin B, it is therefore important in determin- 
ing the final shape of mithramycin (and possibly the 
shape of the related drugs chromomycin and 
olivomycin). In addition, the oxygenase participates in 
the conversion of the biologically inactive premithra- 
mycin B into the active final molecule mithramycin in 
one of the last steps of the mithramycin biosynthesis. 
The MtmOIV oxygenase could be a tool potentially valu- 
able for modifying the architecture of other tetracyclic 
compounds that could be used clinically, helping, there- 
fore, to generate novel lead compounds. 
Materials and methods 
Microorganisms, culture conditions and plasmids 
S. argillaceus ATCC 12956, a mithramycin producer, was used as 
donor of chromosomal DNA. For sporulation on solid medium, it was 
grown at 30% on plates containing A medium [18]. S. a/bus G was 
used as host for transformation. For protoplast transformation 
S. argillaceus and S. albus were grown in YEME medium containing 
17% sucrose. For growth in liquid medium, the organism was grown in 
TSB medium (trypticase soya broth, Oxoid). Escherichia co/i TGl 
recO1504::Tn5 [34] was used as host for subcloning. When plasmid- 
containing clones were grown, the medium was supplemented with 
appropriate antibiotics: 100 wglml for ampicillin, 25 pg/ml apramycin, 
20 pg/ml erythromycin, 50 lg/ml thiostrepton or 20 pg/ml tobramycin. 
pUC18 and pBSK vectors were used for sequencing and subcloning. 
Plasmid pBSKT is a pBluescript derivative containing a thiostrepton 
resistance cassette 1351. pIAGO (351 and pEM4 (361 are bifunctional 
plasmids (Streptomyces-E. co/r) containing the erythromycin resis- 
tance promoter (ennEp) but with different Strepfomyces replicons. 
pUK21 [371 and pKC1218 1381 were used for subcloning. 
DNA manipulation techniques 
Plasmid DNA preparations, restriction endonuclease digestions, alka- 
line phosphatase treatments, ligations and other DNA manipulations 
were according to standard procedures for E. co/i [391 and for Strepfo- 
myces [401. Southern blot hybridization was according to standard 
procedures [40]. DNA sequencing was carried out using the 
dideoxynucleotide chain-termination method 1411 with Taq polymerase 
and an ALF-express automatic DNA sequencer (Pharmacia). To 
overcome band compression artifacts, 7-deaza-dGTP was routinely 
used instead of dGTP [42]. Both DNA strands were sequenced using 
universal primers or internal oligoprimers. Computer-aided database 
searching and sequence analyses were carried out using the University 
of Wisconsin Genetics Computer Group programs package [201 and 
the BLAST program 1241. 
Generation of deletion and insertional inactivation mutants 
For the generation of a deletion mutant lacking the four glycosyltrans- 
ferase and the two methyltransferase genes (mutant M3AMG), a con- 
struct was generated in pBSKT containing a 11.7 kb Psfl-Sa/l DNA 
fragment (sites l-l 4 in Figure 2a) and then the internal 7 kb Fspl-BgAl 
DNA fragment (sites 4-9 in Figure 2a) was replaced by an 
erythromycin resistance gene (err&J orientated in the direction of tran- 
scription. This construct was named pEFAMG. 
For insertional inactivation of mtmO/V, a plasmid construct was gene- 
rated in pBSKT containing a 12 kb Xhol-Bg/ll fragment (sites 6-l 7 in 
Figure 2a) and then an internal 0.4 kb Xhol-Nod fragment (sites 1 l-1 3 
in Figure 2a) was replaced by an apramycin resistance cassette orien- 
tated in the same direction ‘of transcription than mfmO/l/. This con- 
struct was named pLPAO4. 
Both constructs (pEFAMG and pLPAO4) were used to transform pro- 
toplasts of S. argillaceus and transformants selected for resistance to 
etythromycin (pEFAMG) or apramycin (pLPAO4) and then tested for 
their susceptibility to thiostrepton. 
Gene expression 
Plasmid pG14M12 harboring the four mithramycin glycosyltransferases 
and the two methyltransferases was constructed as follows. A 8 kb 
Bglll-Xhol DNA fragment (sites 3-l 1 in Figure 2a) containing the 
3’ end of mtmW, mtmGII/, mtmGIII, mtmMll, mtmMI, mfmG/I, mtmGl 
and the 5’ end of mtmOlV was subcloned into pEM4, generating 
pG14Ml:!. In this construct transcription of mfmG/V, mfmGI//, mfmM// 
and mtmMl genes is under the control of the erythromycin resistance 
promoter :ermE*). The divergent mtmGll and mtmGI genes are tran- 
scribed from their own promoters. 
For expression of mtmOlV, a 2.1 kb BamHl fragment (sites lo-15 in 
Figure 2a) was subcloned under the control of the erythromycin resis- 
tance promoter in the low-copy number vector pKC1218, generating 
pEF04. A similar construct was also made in piAGO (pLPO4). 
Enzymatic assays 
S. albus strains IAGO and LPO4 were grown at 30°C for 48 h in TSB 
medium containing 5 pg/ml thiostrepton. The mycelia were collected by 
centrifugation and washed in 50 mM Tris-HCI (pH 8.0) containing 1 mM 
ethylenediaminotetracetic acid (EDTA) and 1 mM dithiothreitol (DTT). 
Mycelia was broken by ultrasourld (10 pulses 10 s each with intermittent 
cooling on ice water) in a MSEi-ultrasonic disintegrator at 150 W and 
20 kHz. Cell debris were removed by centrifugation at 30,000 x g for 
15 min. The supernatant was fractionated by ammonium sulphate precip- 
itation and ihe precipitates obtained at different salt concentrations dis- 
solved in a small volume of the buffer and extensively dialysed against the 
same buffer. The fractions obtained were used as source for oxygenase 
activity. In t&o activity of the MtmOlV oxygenase was performed in a 
1 ml reaction volume containing 225 wg protein extract, 400pM 
premithramycin B and 1 mM NADH or NADPH. The reaction was carried 
out at 30% for 2 h. Then, the reaction was extracted twice with one 
volume of ethyl acetate after decreasing the pH by adding 100 ~1 HCI 
0.2 N. After evaporation of the solvent, the residue was dissolved in 50 ~1 
methanol and analysed by HPLC as described below. 
HPLC analysis and isolation of mithramycin intermediates 
Spores of drains M3AMG, EF1412 and EF14124 were inoculated in 
TSB medium and incubated for 24 h at 30°C and 250 rpm. The seed 
cultures obtained were used to inoculate (at 2.5% v/v) eight 2 I Erlen- 
meyer flasks each containing 400 ml of modified f75 medium [18]. 
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Media for strains EFl412 and EF14124 contained 2.5 ug/ml thiostrep- 
ton (and 2.5 pg/ml apramycin in the case of EF14124). These cultures 
were incubated as above and formation of mithramycin-related com- 
pounds were monitored by analytical HPLC. After 3 days (strain 
MSAMG) or 4 days (strains EFI 412 and EFI 4124) of incubation, the 
cultures were centrifuged, the supernatants were filtered and applied 
to a solid phase extraction cartridge. Details concerning HPLC and 
extraction were as described previously [18]. The retained compounds 
were eluted with a mixture of methanol and 0.1% trifluoroacetic acid 
(TFA) rn water. A linear gradient from 0% to 1000/o methanol in 60 min, 
at 10 ml/min, was used. Fractions were taken every 5 min and subse- 
quently analyzed by HPLC. Fractions containing the main products 
accumulated by each strain were evaporated, redissolved in a small 
volume of methanol and chromatographed in a (uBondapak Cl 8 radial 
compression cartridge (PrepPak Cartridge 25 x 100 mm, Waters). 
Gradients with acetonitrile and 0.10/o TFA in water, at a flow rate of 
10 mllmin, were optimized for resolution of each peak. The purified 
material collected was applied to a solid phase extraction cartridge 
(Lichrolut RP-18, 500 mg, Merck), washed with water, eluted with 
methanol and dried in vacua. 
Determination of antibiotic activity 
Antibacterial activity was determined by bioassay against Micrococcus 
luteus ATCC 10240 as described [43]. 
Physicochemical properties of premithramycin B 
Rf 0.26 (CHCIsIMeOHlacetic acid/H,0 = 8.34:1:0.5:0.16); IR (KBr): 
v = 3425, 2927, 1634, 1376, 1165, 1067, 613 cm-r; negative FAB 
MS: m/z 1091 ([M-HI-); positive FAB MS: m/z 11 15 ([M+NaI+); UV 
(MeOH) h,, (E) 426.0 (8,200), 335.2 (7,300), 318.7 (8,gOO), 283.0 
(44,100) 230.0 (26,200), 202.0 (19,600) nm; (MeOHINaOH) ?imax (E) 
426.0 (11,700) 280.0 (42,l OO), 228.0 (21,000), 205.0 (25,400) nm; 
(MeOHIHCI) h,,,, (E) 431.0 (7,900), 335.4 (7,800), 321.0 (7,700), 
284.0 (38,900), 230.0 (31,700), 201.0 (19,300) nm; CD (c= 2.36 
lO-5 mol/L, MeOH): h,,,,. ([0]24) 431.4 (-9,000), 342.2 (I 7,400), 
328.4 (13,600) 286.8 (97,100), 264.6 (-29,000), 243.8 (3,300), 
228.6 (-13,700) nm. NMR data: see Tables 1 and 2. 
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